EQT Foundation backs ClexBio, transforming the future of tissue engineered therapies
EQT Foundation joins a funding round for ClexBio to accelerate the development of bioengineered tissues. ClexBio’s proprietary platform offers a new approach to creating complex, lab-grown tissues for human applications. This investment supports ClexBio’s mission to address the significant unmet medical need for advanced tissue therapies, with an initial focus area of liver disease.
EQT Foundation has invested in ClexBio, a Swiss and US-based biotechnology company with roots in Norway, specializing in the development of next-generation tissue therapies. The company leverages a differentiated scientific and technological approach to produce complex tissue structures that closely mimic human biology, opening new possibilities for regenerative medicine. This investment from EQT Foundation, along with other investors including GG1978, will help ClexBio accelerate its development of tissue therapies and position itself as a leader in this emerging field.
ClexBio is tackling a critical challenge in healthcare: the creation of bioengineered tissue for therapeutic use. Existing treatment options for many chronic diseases are not only limited, but also place a significant strain on healthcare systems. This highlights the urgent need for alternative solutions, such as tissue therapeutics, which hold strong potential for a catalytic impact across various diseases and areas of unmet medical need. Among these areas of unmet medical need is liver disease, with the only viable option for liver failure being a transplant, which is not widely available to all due to donor shortages, patient risk profile, and cost. Current cell and tissue therapies often fall short in long-term functionality and therapeutic performance, limiting their application in clinical treatments.
ClexBio’s multicomponent approach is designed to overcome these barriers by combining three different cell types that enhance performance and longevity. ClexBio is starting with a hepatocyte-based liver tissue product to restore function in end-stage liver patients. Their work holds great promise for treating a wide range of chronic diseases, aiming to scale into a multi-indication tissue therapy platform and transforming the way we approach therapeutic treatments.
The EQT Deal Team, consisting of Stefan Niedermaier, Maximilian Moser, and Anjum Rangwala is well-positioned to support ClexBio, particularly with connections to EQT’s Life Sciences portfolio and to industrial advisors in the pharmaceutical and therapeutics sectors.
"ClexBio’s work has the potential to make advanced treatments more accessible and affordable, offering hope to patients facing medical conditions where options are often limited or out of reach.We’ve been impressed by the ambition of this team and are excited to support their journey as ClexBio brings next-generation solutions to patients who need them most."
Cilia Holmes Indahl, CEO EQT Foundation
"We are thrilled to work with the forward-thinking team at EQT Foundation and EQT LifeSciences. With their support, we will be able to accelerate our pre-clinical work to further strengthen our tissue therapeutics platform, moving closer to accessible, off-the-shelf therapies that can significantly improve patient outcomes."
Armend Håti, Founder & CEO Clexbio
"EQT Foundation is excited to support ClexBio, a next-generation tissue therapeutics company applying an innovative approach to develop lab-grown tissues to restore organ function, such as end-stage liver disease. ClexBio addresses critical healthcare needs, focusing on availability, accessibility, and affordability of treatments and we are looking forward to supporting ClexBio leveraging EQT’s broad network and expertise in healthcare and life sciences"
Stefan Niedermaier, EQT Deal Team
"ClexBio's technology and scientific approach is truly transformative and we at EQT Foundation are looking forward to supporting this excellent team in the next phase of growth and impact.'"
Anjum Rangwala, Investor, EQT Foundation
Contact
About EQT
EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of almost three decades of developing companies across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT has EUR 269 billion in total assets under management (EUR 136 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets.
With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.
The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in more than 25 countries across Europe, Asia and the Americas and has more than 1,900 employees.
More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram
About ClexBio
ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough platform for scalable, high-throughput generation of therapeutic tissues. They represent the next generation of cell therapy, leveraging fully functional bioengineered tissues to elevate the restorative ability of cells and produce a new class of curative treatments for some of the world’s most challenging medical conditions.
Exclusive News and Insights Every Week
Add your email address below to sign up for our EQT newsletters.